Section Arrow
CALC.NASDAQ
- CalciMedica
Quotes are at least 15-min delayed:2025/05/31 21:17 EDT
Last
 1.71
-0.0362 (-2.07%)
Day High 
1.71 
Prev. Close
1.7462 
1-M High
2.1513 
Volume 
4.61K 
Bid
1.65
Ask
1.9
Day Low
1.65 
Open
1.7084 
1-M Low
1.524 
Market Cap 
24.40M 
Currency USD 
P/E 0.29 
%Yield -- 
10-SMA 1.82 
20-SMA 1.87 
50-SMA 1.79 
52-W High 5.97 
52-W Low 1.43 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.59/-1.43
Enterprise Value
24.40M
Balance Sheet
Book Value Per Share
0.78
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/05/31 21:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.